Targeted Alpha Therapy - Platform

Offentlig prosjektsammendrag

Unleashing the Power of Alpha: Targeted alpha therapy (TAT) is an emerging cancer treatment that delivers high-energy alpha radiation directly to tumors. This innovative approach offers hope for patients with life-threatening or treatment-resistant cancers. Bayer has a strong history in this field, having been the first to approve a targeted radionuclide therapy for prostate cancer in 2014 (Xofigo developed in Norway), showcasing our expertise in the global development and commercialization of such therapies. We believe TAT can address significant unmet medical needs across various cancer types. Our portfolio includes novel approaches that combine alpha radionuclides with antibodies, peptides, and small molecules for multiple cancer indications. We are dedicated to advancing TATs to support patients with challenging tumors.